MediWound has reported positive top-line results from the Phase III DETECT study after the trial met its primary and secondary endpoints.

DETECT is a prospective, controlled, multi-centre trial of NexoBrid for the treatment of patients with deep partial thickness (DPT) and full thickness (FT) thermal burns.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The primary endpoint of the multi-national, assessor-blinded trial was the complete removal of eschar, measured by comparing all randomised patients in the NexoBrid arm with the patients in the Gel Vehicle control arm.

Results showed that patients who received NexoBrid achieved a significantly higher incidence (93.3%) of complete eschar removal compared with patients treated with gel vehicle (4%).

“These significant results clearly confirm its ability to remove the eschar earlier while significantly reducing patients’ surgical burden.”

Secondary endpoints of the trial comprised reduction in the need for surgical eschar removal, earlier eschar removal, and blood loss, which were assessed against the patients in the standard of care (SOC) control arm.

The trial also compared the time to complete wound closure and other standard safety measures with the SOC control arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MediWound president and CEO Gal Cohen said: “We are thrilled to announce these robust positive results across all endpoints, which corroborate our previous positive EU Phase III clinical study results and clearly demonstrate the significant beneficial impact NexoBrid has on patients’ lives.

“Our innovative product, NexoBrid, represents a new paradigm in burn care management.

“These significant results clearly confirm its ability to remove the eschar earlier while significantly reducing patients’ surgical burden, two outcomes that are both clinically and pharmacoeconomically important.”

MediWound enrolled 175 patients who were randomised in 3:3:1 ratio to receive either NexoBrid, SOC, or the Gel Vehicle placebo as part of the DETECT study,

The trial included 12 and 24-month long-term safety follow-up period. It also included 44 burn centers.